An Oral Fluorouracil Prodrug, Capecitabine, Mitigates a Gram-Positive Systemic Infection in Mice
ABSTRACT New classes of antibiotics are needed to fight bacterial infections, and repurposing existing drugs as antibiotics may enable rapid deployment of new treatments. Screens for antibacterials have been traditionally performed in standard laboratory media, but bacterial pathogens experience ver...
Main Authors: | Jack R. McLeod, Pamela A. Harvey, Corrella S. Detweiler |
---|---|
Format: | Article |
Language: | English |
Published: |
American Society for Microbiology
2021-09-01
|
Series: | Microbiology Spectrum |
Subjects: | |
Online Access: | https://journals.asm.org/doi/10.1128/Spectrum.00275-21 |
Similar Items
-
Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study
by: Jianjun Peng, et al.
Published: (2018-05-01) -
Capecitabine/Mitomycin versus 5-Fluorouracil/Mitomycin in Combination with Simultaneous Integrated Boost Intensity-Modulated Radiation Therapy for Anal Cancer
by: Laurent Mineur, et al.
Published: (2023-09-01) -
Side Effects and Disease-Free Survival with Capecitabine Compared to 5FU for Concurrent Radiochemotherapy of Rectal Cancer: A 5-year Review
by: Peiman Haddad, et al.
Published: (2014-01-01) -
Acute Aortic Thrombosis Following Capecitabine Chemotherapy in a Patient with Colon Cancer
by: Min Kyung Lee, et al.
Published: (2018-09-01) -
Capecitabine versus 5-fluorouracil in colorectal cancer: where are we now?
by: Lakshmi Chintala, et al.
Published: (2011-06-01)